Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djad091
Abstract: BACKGROUND We investigated the role of A2B-adenosine receptor (A2BAR) in regulating immunosuppressive metabolic stress in the tumor microenvironment (TME). Novel A2BAR antagonist PBF-1129 was tested for anti-tumor activity in animals and evaluated for safety and… read more here.
Keywords: adenosine; pbf 1129; efficacy; a2bar ... See more keywords